Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells

被引:0
作者
Yoon, SJ
Park, I
Kwak, C
Lee, E
机构
[1] Seoul Natl Univ, Coll Med, Dept Urol, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110744, South Korea
[3] Gachon Med Sch, Dept Urol, Inchon 405760, South Korea
关键词
bladder cancer; cisplatin; drug resistance; ultrastructural change;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cis-diaminedichloroplatinum (cisplatin) has therapeutic efficacy against advanced bladder cancer. However, the response is often limited due to appearance of drug-resistant tumor cells. Recently, we established a cisplatin-resistant human bladder cancer cell line, T24/R2, from T24 human bladder cancer cell line, which shows 18-fold resistance to cisplatin by the stepwise exposure of increasing concentrations of cisplatin. A light microscopic (LM) and transmission electron microscopic (EM) examination was performed to investigate the morphological and ultrastructural changes during induction of drug resistance. In LM, the cytoplasm of T24R2 cells showed plumper pattern than that of T24 parent cells. In EM, the chromatin pattern of T24R2 cells was finely dispersed compared to T24 cells, which were coarse and aggregated. The mitochondrial volume, rough endoplasmic reticulum, polyribosomes and ribosomes were moderately increased in T24R2 cells. The cell membrane showed ruffled border and great amount of double membrane vesicles and pinocytic vesicles were observed in the cell surface of T24R2 cells, which were seldom observed in T24 cells. With these findings, we concluded that human bladder cancer cells underwent morphological and ultrastructural changes during acquiring of resistance to cisplatin. We could suggest that these changes might be be involved in the drug resistance mechanism in human bladder cancer cells.
引用
收藏
页码:1363 / 1367
页数:5
相关论文
共 19 条
  • [1] ANDREWS PA, 1992, CANCER RES, V52, P1895
  • [2] ALTERED PLASMA-MEMBRANE ULTRASTRUCTURE IN MULTIDRUG-RESISTANT CELLS
    ARSENAULT, AL
    LING, V
    KARTNER, N
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 938 (02) : 315 - 321
  • [3] CARMICHAEL J, 1987, CANCER RES, V47, P936
  • [4] CORNWELL MM, 1986, J BIOL CHEM, V261, P7921
  • [5] DIETEL M, 1990, CANCER RES, V50, P6100
  • [6] ERLANDSON RA, 1994, DIAGNOSTIC TRANSMISS, P69
  • [7] A STUDY OF HUMAN SMALL-CELL LUNG-CARCINOMA (HSCLC) CELL-LINES WITH DIFFERENT SENSITIVITIES TO DETECT RELEVANT MECHANISMS OF CISPLATIN (CDDP) RESISTANCE
    HOSPERS, GAP
    MEIJER, C
    DELEIJ, L
    UGES, DRA
    MULDER, NH
    DEVRIES, EGE
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (01) : 138 - 144
  • [8] EFFECT OF GLUTATHIONE ON DNA-REPAIR IN CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELL-LINES
    LAI, GM
    OZOLS, RF
    YOUNG, RC
    HAMILTON, TC
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (07): : 535 - 539
  • [9] DIFFERENTIATION OF A HUMAN RHABDOMYOSARCOMA CELL-LINE AFTER ANTINEOPLASTIC DRUG-TREATMENT
    MELGUIZO, C
    PRADOS, J
    ANEIROS, J
    FERNANDEZ, JE
    VELEZ, C
    ARANEGA, A
    [J]. JOURNAL OF PATHOLOGY, 1995, 175 (01) : 23 - 29
  • [10] PERRY JJ, 1994, UROL CLIN N AM, V21, P661